{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:40:21Z","timestamp":1782351621565,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"am","delay-in-days":266,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54-CA225088"],"award-info":[{"award-number":["U54-CA225088"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","award":["R35GM142879"],"award-info":[{"award-number":["R35GM142879"]}],"id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110819"],"award-info":[{"award-number":["W81XWH2110819"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AR077073"],"award-info":[{"award-number":["K23AR077073"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jaad.2023.02.014","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T02:15:14Z","timestamp":1677032114000},"page":"1308-1316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy"],"prefix":"10.1016","volume":"88","author":[{"given":"Nga","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Ugwu-Dike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora A.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruple","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Phillipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Roster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayhyun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia S.","family":"DeSimone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Theodosakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munachimso","family":"Amadife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevada","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Hurlbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Hsing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hensin","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7387-3094","authenticated-orcid":false,"given":"Yevgeniy R.","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2023.02.014_bib1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/cam4.1001","article-title":"A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma","volume":"6","author":"da Silveira Nogueira Lima","year":"2017","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.jaad.2023.02.014_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3899\/jrheum.190084","article-title":"Immune-related adverse events associated with cancer immunotherapy: a review for the practicing rheumatologist","volume":"47","author":"Jamal","year":"2020","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.02.014_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.02.014_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.02.014_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.02.014_bib6","series-title":"Cutaneous immune-related adverse events are protective of patient survival in advanced cancer patients - a multi-institutional cohort study (Abstract). Presented at the: American Academy of Dermatology Annual Meeting; March 26, 2022","author":"Zhang","year":"2022"},{"key":"10.1016\/j.jaad.2023.02.014_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1758834018757175","article-title":"Treatment of uveal melanoma: where are we now?","volume":"10","author":"Yang","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jaad.2023.02.014_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.680407","article-title":"Immunotherapy in acral and mucosal melanoma: current status and future directions","volume":"12","author":"Mao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2023.02.014_bib9","first-page":"1044","article-title":"Calculating the benefits of a Research patient data repository","volume":"2006","author":"Nalichowski","year":"2006","journal-title":"AMIA Annu Symp Proc"},{"key":"10.1016\/j.jaad.2023.02.014_bib11","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"Levesque","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2023.02.014_bib12","series-title":"Statistical Software: Release 17","year":"2021"},{"issue":"9","key":"10.1016\/j.jaad.2023.02.014_bib13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2023.02.014_bib14","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jdv.16311","article-title":"Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients","volume":"34","author":"Bottlaender","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.014_bib15","article-title":"Cutaneous adverse events of immune checkpoint inhibitors: a literature review","volume":"11","author":"Apalla","year":"2021","journal-title":"Dermatol Pract Concept"},{"issue":"9","key":"10.1016\/j.jaad.2023.02.014_bib16","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s12094-019-02033-x","article-title":"Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma","volume":"21","author":"Castaneda","year":"2019","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"10.1016\/j.jaad.2023.02.014_bib17","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s12094-017-1685-3","article-title":"Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America","volume":"19","author":"Castaneda","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jaad.2023.02.014_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.jaad.2023.02.014_bib19","first-page":"4155","article-title":"Tumor infiltrating lymphocytes: the regulator of melanoma evolution","volume":"17","author":"Antohe","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jaad.2023.02.014_bib20","doi-asserted-by":"crossref","first-page":"524700","DOI":"10.3389\/fonc.2020.524700","article-title":"Poor lymphocyte infiltration to primary tumors in acral lentiginous melanoma and mucosal melanoma compared to cutaneous melanoma","volume":"10","author":"Nakamura","year":"2020","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2023.02.014_bib21","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","article-title":"Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma","volume":"77","author":"Clemente","year":"1996","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jaad.2023.02.014_bib22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","article-title":"Melanoma subtypes demonstrate distinct PD-L1 expression profiles","volume":"97","author":"Kaunitz","year":"2017","journal-title":"Lab Invest"},{"issue":"6","key":"10.1016\/j.jaad.2023.02.014_bib23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10637-016-0373-4","article-title":"Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry","volume":"34","author":"Cho","year":"2016","journal-title":"Invest New Drugs"},{"issue":"25","key":"10.1016\/j.jaad.2023.02.014_bib24","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2023.02.014_bib25","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3390\/ijms21030879","article-title":"The role of immune checkpoint blockade in uveal melanoma","volume":"21","author":"Wessely","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.jaad.2023.02.014_bib26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.014_bib27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/annonc\/mdt411","article-title":"Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas","volume":"25","author":"Egberts","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2023.02.014_bib28","article-title":"1263 Dermatologic immune related adverse event disease definitions: a multi-institutional Delphi consensus project presented on behalf of the oncodermatology working group","volume":"10","author":"Chen","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.jaad.2023.02.014_bib29","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.jid.2022.05.222","article-title":"215 Cutaneous immune-related adverse events predict longer patient survival in advanced cancer patients","volume":"142","author":"Lu","year":"2022","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jaad.2023.02.014_bib30","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study","author":"Zhang","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223002049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223002049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:36:33Z","timestamp":1777523793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223002049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0190962223002049"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.014","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}